Dr Javed Butler: Vericiguat & Low GFR

Dr. Javed Butler explores the critical interplay between heart failure and chronic kidney disease, emphasizing how worsening renal function increases the risk of hospitalization and mortality. He highlights the irony that patients with the greatest need for therapy often receive the least due to contraindications and concerns about safety in low GFR settings. Vericiguat emerges as a breakthrough, being tested in patients with GFR as low as 15 ml/min—the lowest inclusion criteria in heart failure trials. Dr. Butler confirms its safety and efficacy across the renal function spectrum, providing a much-needed option for high-risk heart failure patients with renal impairment.